FAQs
CAN I INVEST IN NANOSCENT?
Currently, we are a privately held company where we invite strategic investors into the company, such as big corporations. We are open to discuss and would love to hear from you. Please contact us. To get an idea, our current strategic investors are DreamTech and Sumitomo Chemicals. Both are involved in our development, production, and distribution efforts.
WHAT IS THE FUNDING STATUS?
Since our establishment in 2017, we have raised $19 million. From this amount, $9million come from grants, such as from the European Innovation Council and the Innovation Israel Authority, and projects with Fortune 500 companies. NanoScent has also raised $10million in equity from our strategic investors.
HOW CAN I REQUEST A DEMO?
Currently, we are in the development stages and are happy to share our prototype samples for corporate customers who are interested in seeing the user-experience of our technology. If you are interested, please let us know about your company background to see if you are qualified by contacting us.
DO YOU ACCEPT STUDENTS?
For NanoScent, having students on the team is very important. We try to cultivate students at an early stage and want to give them the opportunity to learn and grow with us. At any given time, we have interns or students working as part-time technicians in various parts of the company, include the the lab, as well as clinical and marketing roles. And our wish for students is to grow, possibly even to join the company in the future. If this sounds interesting to you, please contact us.
WHEN IS REGULATORY APPROVAL EXPECTED?
NanoScent is following the regulatory path in different countries with some of the best regulatory bodies in the world in order to meet the requirements for screening coronavirus based on the most rigorous standards. Our aim is to make our VOCID® the first approved breath diagnostic device.
WHAT IS THE STATUS OF THE TECHNOLOGY?
Our team is dedicated to develop scent recognition technology from an academic concept to a usable product with industrial standards. At present time, our technology performs at high sensitivity (at 50 PPB) and shows promise for implementation in different settings with our current focus being on clinical and medical settings.
DOES NANOSCENT HOLD PATENTS?
Yes. The NanoScent teams has 7 patents for the scent recognition technology that drives VOCID®. Our patents cover many important areas, from sensor production to methodology and machine-learning. To read more about our patents, please visit our Technology page for additional information.
HAS NANOSCENT PERFORMED CLINICAL TRIALS?
Our clinical team is very strong and is able to conduct clinical trials in complex environments that are difficult logistically. When COVID-19 first emerged, our team collected over 3000 breath samples across various settings. Currently, we are working with Fisabio Foundation and Owlstone Medical in a trial designed to validate our tech to meet regulatory approval requirements.